Sleep drug could quiet breathing pauses in apnea

NCT ID NCT07683442

Not yet recruiting Disease control Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial investigates whether lemborexant, a sleep medication, can reduce the number of breathing pauses in adults with moderate obstructive sleep apnea who have a low arousal threshold (wake up easily). Participants take either lemborexant or a placebo daily for 30 days in three separate phases. The main goal is to see if the drug lowers the apnea-hypopnea index (AHI), a measure of breathing interruptions during sleep.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lemborexant (Dayvigo)
What this could lead to: If it works, lemborexant could offer a new medication option for people with moderate sleep apnea who wake up too easily during sleep.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply to everyone. The drug may not improve apnea enough to be clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSA - OBSTRUCTIVE SLEEP APNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apnea obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSA - OBSTRUCTIVE SLEEP APNEA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chulalongkorn University

Pathum Wan, Bangkok, 10330, Thailand

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.